February 2026 Options Now Available For The Cigna Group (CI)

At CI (The Cigna Group) trading at $273.56, a sell-to-open $270 put (bid $9.10) would set an effective cost basis of $260.90 and is ~1% out-of-the-money; current analytics show a 58% chance it expires worthless, yielding 3.37% on cash committed (27.96% annualized). A covered-call at the $275 strike (bid $11.40) against existing shares would cap upside at $275 and, if called at the Feb 2026 expiration, produce a 4.69% total return (4.17% boost if the call expires worthless) with a 48% probability of expiring worthless. Implied volatilities are ~35% (put) and 36% (call) versus a 12‑month trailing volatility of 34%; figures exclude broker commissions and dividends.

Analysis

Market structure: The option quotes on CI (CI) signal dealer willingness to provide short-dated yield (puts bid $9.10 at 270, calls $11.40 at 275) with implied vol 35–36% vs realized 34%, suggesting market-neutral risk pricing. Direct winners are option sellers and yield-seeking cash allocators who can accept assignment; losers are directional buyers who pay elevated premia and long-only holders who face capped upside if writing calls. Cross-asset impact is small but relevant: a large shift into selling insurance equity puts would compress equity volatility while nudging short-term hedging flows in single-stock equity options, with minimal immediate effect on Treasuries/FX unless a macro shock re-prices rates.

Risk assessment: Tail risks include regulatory moves on insurer margins, large claim shocks (pandemic or catastrophic litigation), and a surprise downgrade; a >10% adverse move in CI before Feb 2026 would overwhelm option income. Immediate (days) risk is IV re-pricing around earnings; short-term (weeks–months) is assignment/roll risk into Feb 2026; long-term depends on underwriting trends and M&A. Hidden dependencies: realized vol divergence from implied vol, block order liquidity, and collateral/margin demands if multiple short contracts are held. Key catalysts: CI earnings, CMS policy updates, and macro-driven healthcare utilization data over the next 30–90 days.

Trade implications: Income play — sell-to-open CI 270 put (collect $9.10) if willing to own at effective $260.90, size 1–2% NAV, roll or close if CI < $250 or IV >50%. Covered-call — buy CI at $273.56 and sell 275 Feb 2026 call to earn ~4.7% to expiry; cap upside but collect 11.40 now. Volatility play — avoid long straddles given IV≈realized; instead, buy cheap downside protection (put spread 1–2% notional) if net short premium exposure.

Contrarian angles: Consensus treats these trades as conservative yield boosts but underestimates assignment concentration risk and event-driven IV spikes; the annualized YieldBoost numbers (28–35%) overstate net returns when adjusted for drawdowns and capital at risk. Historical parallel: insurer option income strategies paid in stable-rate regimes but faltered under sudden claims inflation (2017–18 catastrophe years). Unintended consequence — aggressive put-writing could force institutional buyers into concentrated share ownership, amplifying downside on negative news.

Key Decisions for Investors

• Establish a defined-risk income trade: sell-to-open 1–2% NAV equivalent of CI Feb 2026 270 puts (collect $9.10) only if prepared to buy at $260.90; set a hard exit/roll if CI < $250 or IV spikes above 50% within 30 days.
• Create a covered-call sleeve: acquire up to 1–3% NAV in CI and sell Feb 2026 275 calls (collect $11.40) to generate ~4.7% gross return; plan to buy back calls if CI > $285 or if upcoming catalyst (earnings/CMS) raises IV by >20%.
• Hedge concentrated short-premium exposure with a cheap put spread: buy CI Feb 2026 240/220 put spread sized at 25–50% of short-put notional to cap tail loss; accept cost if protecting assignment risk beyond a 10% decline.
• Relative-value pair: if bullish on CI fundamentals vs peers, go long CI (1–2% NAV) and short UNH or CVS (1% NAV) to express idiosyncratic rebound while hedging sector beta; close if CI underperforms peer by >5% over 60 days.